Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01607385 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01607385 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 56 participants.
The verdict
NCT01607385, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with a single day of dosing with GSK1614235
Interventions
- DRUG Placebo
- DRUG GSK2330672
- DRUG GSK1614235
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-05-18 |
| Est. Completion | 2012-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01607385
The ClinicalTrials.gov registry entry for NCT01607385 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01607385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01607385 about?
NCT01607385 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.". A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with a single day of dosing with GSK1614235
What is the current status of trial NCT01607385?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2012-05-18. Estimated completion is 2012-12-03.
What interventions are being tested in trial NCT01607385?
The interventions under investigation include: Placebo (DRUG), GSK2330672 (DRUG), GSK1614235 (DRUG).
Who is sponsoring clinical trial NCT01607385?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.